Sotoclaro combined with R-CHOP regimen for the treatment of newly diagnosed aggressive B-cell lymphoma with BCL2 positivity: A multicenter, single-arm, open-label Ib/II phase clinical study (ChiCTR) - Oct 16, 2026 - P1/2 | N=43 | Not yet recruiting | Sponsor: Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
New P1/2 trial • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • BCL2
|